Ryan Specialty (NYSE:RYAN) Rating Lowered to Peer Perform at Wolfe Research

Ryan Specialty (NYSE:RYAN - Get Free Report) was downgraded by Wolfe Research from an "outperform" rating to a "peer perform" rating in a research note issued to investors on Monday, MarketBeat.com reports.

RYAN has been the topic of a number of other research reports. JPMorgan Chase & Co. lifted their price target on shares of Ryan Specialty from $47.00 to $49.00 and gave the company an "underweight" rating in a research report on Monday, April 8th. Wells Fargo & Company lifted their price target on shares of Ryan Specialty from $57.00 to $58.00 and gave the company an "overweight" rating in a research report on Thursday, April 11th. JMP Securities reissued a "market perform" rating on shares of Ryan Specialty in a research report on Monday, April 15th. Citigroup raised their price objective on shares of Ryan Specialty from $49.00 to $52.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 28th. Finally, Keefe, Bruyette & Woods raised their price objective on shares of Ryan Specialty from $56.00 to $62.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 10th. One analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $54.25.

View Our Latest Stock Report on Ryan Specialty


Ryan Specialty Stock Down 0.0 %

RYAN traded down $0.01 during midday trading on Monday, hitting $51.49. 782,990 shares of the company's stock traded hands, compared to its average volume of 780,492. The company has a market cap of $13.40 billion, a PE ratio of 97.15 and a beta of 0.58. The stock's fifty day simple moving average is $52.56 and its 200-day simple moving average is $47.08. The company has a debt-to-equity ratio of 1.98, a current ratio of 1.16 and a quick ratio of 1.16. Ryan Specialty has a one year low of $39.44 and a one year high of $56.51.

Ryan Specialty (NYSE:RYAN - Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.35 EPS for the quarter, meeting analysts' consensus estimates of $0.35. Ryan Specialty had a net margin of 9.15% and a return on equity of 46.11%. The company had revenue of $552.00 million for the quarter, compared to analyst estimates of $549.06 million. During the same quarter last year, the firm posted $0.26 earnings per share. The company's quarterly revenue was up 20.6% compared to the same quarter last year. As a group, equities analysts anticipate that Ryan Specialty will post 1.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ryan Specialty

A number of institutional investors have recently bought and sold shares of RYAN. Raymond James & Associates boosted its stake in Ryan Specialty by 637.8% during the third quarter. Raymond James & Associates now owns 42,318 shares of the company's stock worth $2,048,000 after buying an additional 36,582 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Ryan Specialty by 16.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 391,946 shares of the company's stock valued at $18,970,000 after purchasing an additional 55,828 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Ryan Specialty by 33.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,002 shares of the company's stock valued at $968,000 after purchasing an additional 5,037 shares in the last quarter. First Horizon Advisors Inc. boosted its stake in shares of Ryan Specialty by 27.6% in the 3rd quarter. First Horizon Advisors Inc. now owns 2,409 shares of the company's stock valued at $117,000 after purchasing an additional 521 shares in the last quarter. Finally, CHICAGO TRUST Co NA acquired a new stake in shares of Ryan Specialty in the 3rd quarter valued at $212,000. Institutional investors and hedge funds own 84.82% of the company's stock.

About Ryan Specialty

(Get Free Report)

Ryan Specialty Holdings, Inc operates as a service provider of specialty products and solutions for insurance brokers, agents, and carriers in the United States, Canada, the United Kingdom, Europe, and Singapore. It offers distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.

Further Reading

Analyst Recommendations for Ryan Specialty (NYSE:RYAN)

→ The CHIPS Act Motherlode (From True Market Insiders) (Ad)

Should you invest $1,000 in Ryan Specialty right now?

Before you consider Ryan Specialty, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ryan Specialty wasn't on the list.

While Ryan Specialty currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Featured Articles and Offers

Search Headlines: